Limbic Predominant Age Related Tdp 43 Encephalopathy (Late) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE) is a recently recognized neurodegenerative condition characterized by TDP-43 protein pathology predominantly affecting the limbic system, particularly in older adults. First described in 2019, LATE represents an underappreciated cause of dementia that often mimics Alzheimer's Disease but has distinct pathological features.
Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently recognized neurodegenerative disease characterized by the accumulation of misfolded TDP-43 protein in the limbic system, particularly the amygdala and hippocampus. First formally defined by a consensus working group in 2019, LATE produces a clinical syndrome that closely mimics Alzheimer's disease but has distinct molecular pathology.[1]
LATE is among the most common causes of dementia in older adults, affecting approximately 20–50% of individuals over age 80 at autopsy. The condition frequently co-occurs with Alzheimer's Disease neuropathologic change, and when both pathologies are present, cognitive decline is more severe than with either alone.[2]
LATE neuropathologic change (LATE-NC) is remarkably prevalent in the aging brain:
- Autopsy studies detect LATE-NC in approximately 25% of brains from community-based cohorts of individuals over age 80[1]
- An estimated 15–20% of clinically diagnosed Alzheimer's Disease cases in the oldest old (age 80+) may actually be attributable to LATE[2]
- Prevalence increases sharply with age: rare before age 70, increasingly common after age 80, and very common after age 90
- In the oldest old (90+), LATE-NC may be more prevalent than Alzheimer's-type pathology alone
- Age: The strongest risk factor; LATE is overwhelmingly a disease of advanced age
- Female sex: Women appear to be at modestly higher risk
- Genetic factors: Variants in TMEM106B, GRN (encoding progranulin, [ABCC9], KCNMB2, and APOE, a nuclear RNA-binding protein that normally regulates mRNA splicing, stability, and transport. In LATE:
- Nuclear depletion: TDP-43 is depleted from the nucleus of affected neurons
- Cytoplasmic accumulation: Hyperphosphorylated, ubiquitinated TDP-43 aggregates form cytoplasmic inclusions
- Loss of normal function: Nuclear depletion impairs RNA processing, including cryptic exon splicing
- Gain of toxic function: Cytoplasmic aggregates disrupt cellular processes and may seed further aggregation
This TDP-43 pathology is shared with ALS and frontotemporal lobar degeneration (FTLD-TDP), but in LATE, the distribution is distinctly limbic-predominant rather than involving motor neurons or frontotemporal cortex.[5]
LATE neuropathologic change follows a stereotypical spatial progression:[1]
| Stage |
Region Affected |
Description |
| Stage 0 |
None |
No TDP-43 cytoplasmic inclusions detected |
| Stage 1 |
amygdala |
TDP-43 inclusions restricted to the amygdala |
| Stage 2 |
hippocampus |
Spread to hippocampus and entorhinal cortex |
| Stage 3 |
Neocortex |
Extension to middle frontal gyrus and additional neocortical regions |
Higher stages correlate with greater cognitive impairment. Stage 1 may be asymptomatic, while stages 2 and 3 are associated with progressive memory loss and clinical dementia.
A frequent companion pathology in LATE is hippocampal sclerosis of aging (HS-Aging), characterized by:
- Severe neuronal loss in the CA1 sector and subiculum of the hippocampus
- Reactive gliosis with astrocytes and [microglial activation
- Disproportionate hippocampal atrophy visible on MRI
Hippocampal sclerosis is present in approximately 10–25% of LATE cases and is associated with more severe memory impairment.[6]
LATE-NC frequently co-occurs with other neuropathologies:
- Alzheimer's Disease neuropathologic change (ADNC): amyloid-beta plaques and tau] neurofibrillary tangles. Combined LATE + AD leads to worse cognitive outcomes than either alone
- Age-related tau astrogliopathy (ARTAG): Tau deposits in astrocytes, common in aging
- Cerebrovascular disease: Arteriolosclerosis, microinfarcts, and white matter changes
- [Lewy body pathology]: [alpha-synuclein/proteins/alpha deposits may also co-occur
Several genetic loci have been replicated as risk factors for LATE-NC:[3]
| Gene |
Variant |
Effect |
Notes |
| TMEM106B |
rs1990622 |
Risk/protection |
Also associated with [FTLD-TDP]; modulates TDP-43 aggregation |
| GRN |
rs5848 |
Risk |
Encodes progranulin; complete GRN loss causes FTLD; partial loss contributes to LATE |
| [APOE |
ε4 allele |
Risk |
Shared risk factor with Alzheimer's disease |
| SORL1 |
Multiple variants |
Risk |
Also associated with Alzheimer's Disease |
| ABCC9 |
rs1914361, rs701478 |
Risk |
Encodes SUR2 potassium channel subunit; linked to vascular pathology |
| KCNMB2 |
Multiple variants |
Risk |
Encodes potassium channel subunit |
The shared genetic architecture between LATE and [FTLD-TDP] (via GRN and TMEM106B) and with Alzheimer's disease (via APOE and SORL1) suggests converging biological pathways despite distinct clinical presentations.[7]
LATE presents as a slowly progressive amnestic dementia syndrome that is clinically indistinguishable from Alzheimer's Disease during life:
- Memory impairment: The predominant feature; similar to early Alzheimer's disease
- Slower progression: Generally progresses more slowly and is milder than typical Alzheimer's
- Later onset: Typically manifests after age 80, later than typical Alzheimer's Disease
- Preserved executive function: Executive and visuospatial abilities may be relatively spared in early stages
- Behavioral changes: Can include apathy, depression, and personality changes in advanced stages
| Feature |
LATE |
Alzheimer's disease |
| Typical onset age |
>80 years |
60–80 years (late-onset) |
| Core protein |
TDP-43 |
amyloid-beta and tau] |
| Brain regions |
Limbic (amygdala, hippocampus) |
Widespread cortical |
| amyloid PET |
Negative (pure LATE) |
Positive |
| Progression rate |
Slower |
Moderate to rapid |
| Genetic risk |
TMEM106B, GRN, APOE |
APOE, APP, PSEN1, PSEN2 |
LATE can only be definitively diagnosed at autopsy through neuropathological examination for TDP-43 inclusions. During life, a clinical diagnosis of "probable LATE" is increasingly feasible using a combination of approaches.[8]
In 2025, the first clinical diagnostic criteria for LATE were published:[8]
- Probable LATE: Amnestic dementia syndrome in an individual over 80 years with negative amyloid biomarkers (amyloid PET or CSF amyloid
- Possible LATE: Amnestic dementia syndrome with amyloid biomarkers unavailable, or when amyloid is present (since LATE and Alzheimer's frequently co-occur)
- MRI: Limbic-predominant atrophy pattern, particularly hippocampal atrophy disproportionate to overall cortical atrophy
- PET imaging: Amyloid-negative status in the setting of dementia is suggestive
- Blood-based biomarkers: Plasma NfL (neurofilament light chain) elevation; absence of amyloid-beta and tau biomarker signatures
- TDP-43-specific biomarkers: Under development but not yet clinically available
- Hippocampal atrophy: Often severe; may include frank hippocampal sclerosis
- Medial temporal atrophy: Prominent amygdala and entorhinal cortex atrophy
- Relative cortical sparing: Less global cortical atrophy than in typical Alzheimer's
- FDG-PET: Limbic-predominant hypometabolism
¶ Treatment and Management
There are no approved treatments specifically targeting LATE. Current management is supportive:
- Symptomatic treatment: Cholinesterase inhibitors and memantine (as used in Alzheimer's) may provide modest benefit, though their efficacy specifically in LATE has not been established
- Behavioral management: Non-pharmacological approaches for dementia symptoms
- Caregiver support: Similar to other dementia care
- Comorbidity management: Cardiovascular risk reduction given frequent co-occurrence with cerebrovascular disease
The recognition of LATE has important implications for Alzheimer's therapeutics:
- Clinical trial design: Anti-amyloid therapies (e.g., lecanemab, donanemab) are unlikely to benefit patients with pure LATE
- Diagnostic screening: LATE may explain why some "Alzheimer's" patients do not respond to amyloid-targeted therapies
- New drug targets: TDP-43 aggregation, GRN/progranulin pathways, and TMEM106B may represent therapeutic targets
- Development of TDP-43-specific PET tracers for in vivo diagnosis
- Blood-based biomarkers to distinguish LATE from Alzheimer's Disease
- Clinical trials specifically targeting TDP-43 pathology
- Understanding the biology of selective vulnerability of limbic structures
- Investigation of the ABCC9/SUR2 pathway as a potential drug target[3]
- 2019: Consensus working group formally defined LATE as a distinct disease entity (Nelson et al., Brain)[1]
- 2022: Updated LATE-NC staging guidelines published (Acta Neuropathologica)[9]
- 2024: Population-based study in the oldest old confirmed LATE prevalence rates[10]
- 2025: First clinical diagnostic criteria for probable/possible LATE published (Wolk et al., Alzheimer's & Dementia)[8]
- Biomarker discovery: Development of blood and CSF biomarkers specific to LATE-NC
- TDP-43 imaging: PET tracers for TDP-43 pathology remain a major unmet need
- Genetic epidemiology: Large-scale GWAS studies across diverse populations
- Animal models: Development of age-dependent TDP-43 limbic pathology models
- Co-pathology interactions: Understanding how LATE-NC and Alzheimer's pathology synergize
The study of Limbic Predominant Age Related Tdp 43 Encephalopathy (Late) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Nelson et al., Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report (2019)https://pubmed.ncbi.nlm.nih.gov/31039256/)
- [Kapasi et al., Limbic-predominant age-related TDP-43 encephalopathy in the oldest old: a population-based study (2024)]https://academic.oup.com/brain/article/148/1/154/7700928)
- [Nelson et al., LATE-NC: Co-pathologies and genetic risk factors provide clues about pathogenesis (2024)]https://pubmed.ncbi.nlm.nih.gov/38613823/)
- [Katsumata et al., LATE-NC risk alleles among persons with African ancestry (2023)]https://pmc.ncbi.nlm.nih.gov/articles/PMC10440720/)
- [Ling et al., TDP-43 pathology in neurodegenerative disease (2013)]https://pubmed.ncbi.nlm.nih.gov/23463272/)
- [Nelson et al., Hippocampal sclerosis in advanced age: clinical and pathological features (2013)]https://pubmed.ncbi.nlm.nih.gov/23524847/)
- [Nelson et al., Analysis of genes implicated in risk for LATE-NC and hippocampal sclerosis (2021)]https://pubmed.ncbi.nlm.nih.gov/34526147/)
- [Wolk et al., Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy (2025)]https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14202)
- [Nelson et al., LATE-NC staging in routine neuropathologic diagnosis: an update (2023)]https://link.springer.com/article/10.1007/s00401-022-02524-2)
- [Robinson et al., LATE-NC: clinicopathologic features and biomarkers (2022)]https://pubmed.ncbi.nlm.nih.gov/36190653/)